DOCSLIB.ORG

Identification of New Amphetamine-Related Designer Drugs Using Exactive High Resolution Accurate Mass Spectrometry Giampietro Frison

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2011 Joint SOFT-TIAFT Meeting San Francisco, California, USA Thermo Scientific Workshop 28 September 2011 Identification of New Amphetamine-Related Designer Drugs Using Exactive High Resolution Accurate Mass Spectrometry Giampietro Frison Laboratory of Environmental Hygiene and Forensic Toxicology Department of Prevention Azienda ULSS 12 Veneziana, Mestre (Venezia), Italy Forensic Toxicology Use Only Forensic toxicology at the LIATF Seized drugs • Determination of active ingredients, adulterants, diluents in seized material for Police and Court Biological samples • Determination of alcohol, psychoactive drugs, other drugs of toxicological interest in biofluids • Driving under the influence of alcohol and drugs • Post-mortem toxicology • Drug-facilitated crimes • Other forensic toxicology applications Forensic Toxicology Use Only The flood of new designer drugs Indane analogues of Ecstasy’s (MDAI, MDMAI) Tetraline analogues of Ecstasy’s (2-AT, MDAT) Tryptamines Cannabinomimetics (JWH-18, JWH-073, JWH-200, JWH-250,CP-47,497, ... ) Beta-keto-amphetamines (designer cathinones) Piperazines Forensic Toxicology Use Only New A-R drugs encountered at LIAFT Mephedrone 4-MEC 4-FA MDPV Methylone Cl-Ph-Pip propyl Propylone Forensic Toxicology Use Only The flood of new designer drugs ? ? ?? ? The LIAFT experience with new designer drugs Increasing number of police seizures and/or intoxication cases Need to promptly obtain their structural characterization , in spite of poor availability of reference (p/m) standards Forensic Toxicology Use Only Analytical strategy to obtain the structural characterization of new A-R drugs GC-MS GC-MS + der UHPLC-HRMS underiv. drugs with 3ClEtClfor (Orbitrap) Poor chromatography Improved GC properties Accurate mass measurements at 100.000 resolv. power Non-specific EI MS Distinctive MS behav. Study of MH + collision- Highly inform. EI MS induced product ions Comparison of exp. and calc. MH + isotopic clusters Study of isotopic fine structure of M+1, M+2, M+3 clusters Forensic Toxicology Use Only GC/MS - Mephedrone Rel. Ab. 6.31 Mephedrone (4-Methyl-Meth-Cathinone) Methanolic solution (b.p. 64.5 °C) 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 Time GC/MS Agilent 7890 II - 5975 Agilent HP-5MS Ultra Inert column Full Scan EI (40-450 u) 30 m x 0.25 mm x 0.25 µm Inj. 1 µl, 250C, split / splitless (1 min) 50C (0.5 min), 200C a 30C/min, 300C (5 min) a 10C/min Carrier gas (He), 1 ml/min Interf. 280C, EMV + 300 V Forensic Toxicology Use Only GC/MS - Mephedrone Rel. Ab. 58 MW 177 56 65 91 119 162 0 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 m/z GC/MS Agilent 7890 II - 5975 Agilent HP-5MS Ultra Inert column Full Scan EI (40-450 u) 30 m x 0.25 mm x 0.25 µm Inj. 1 µl, 250C, split / splitless (1 min) 50C (0.5 min), 200C a 30C/min, 300C (5 min) a 10C/min Carrier gas (He), 1 ml/min Interf. 280C, EMV + 300 V Forensic Toxicology Use Only Mephedrone deriv. with 3ClEtClfor + Cl CO O CH 2 CCl 3 50 µL 2,2,2 - 3ClEtClfor : Ethyl acetate 3 : 7 MW 177 80 °C, 15 min, to dryness Residue reconst. with 50 µL Ethyl acetate CH 3 C O CH 2 CCl 3 O MW 351 Forensic Toxicology Use Only GC/MS of Mephedrone - 3ClEtClfor Rel. Ab. 11.08 Mephedrone – 3ClEtClfor 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00 15.00 Time GC/MS (same instrument, same conditions) Agilent 7890 II - 5975 Agilent HP-5MS Ultra Inert column Full Scan EI (40-450 u) 30 m x 0.25 mm x 0.25 µm Inj. 1 µl, 250C, splitless (1 min) 50C (0.5 min), 200C a 30C/min, 300C (5 min) a 10C/min Carrier gas (He), 1 ml/min Interf. 280C, EMV + 300 V Forensic Toxicology Use Only GC/MS of Mephedrone - 3ClEtClfor . 91 + CH 3 Cl 351 353 Cl 355 C O CH 2 C Cl O 131 232 204 133 316 119 234 135 318 236 Rel. Ab. 232 234 58 91 119 131 236 133 65 135 351 160 316 204 353 318 355 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 m/z Forensic Toxicology Use Only U-HPLC/HR-Orbitrap-MS and A-R drugs Why choosing the Orbitrap technology r z k ω = m / z φ Non-targeting approach (Full Scan) and “all ions” MS/MS Retrospective detection of analytes without new MS runs High resolving power: 100.000 at m/z 200 High mass accuracy: < 5ppm (e.c.), < 2ppm (i.c.) High mass accur. for M+0 and M+1, M+2, ....ions: EC assign. with high confidence 100.000 RP: full separation of 15 N from M+1 C isotope, and 34 S from M+2 C isotope Forensic Toxicology Use Only U-HPLC/HR-Orbitrap-MS and A-R drugs U-HPLC Thermo Scientific LC: U-HPLC Thermo Scientific Accela 1250 Exactive HCD MS Injection: 10 µL Column: Thermo Scientific Hypersil Gold 50 x 2.1 mm x 1.9 mcm Phase A: H2O, 0,05% HCOOH, 5 mM HCOONH 4,pH 5 Phase B: ACN, 0,05% HCOOH Analytical Conditions Flow: 400 µL/min Gradient: 2% B, to 30% B in 5 min, to 98% B in 5 min, maint. 2 min, to 2% B in 4 min, maint. 2 min. Temp.: Column 40 °C, samples 15 °C HR-Orbitrap-MS Mass detect.: Thermo Scientific “Exactive” Orbitrap HRMS Source: HESI-II Ion Max Spray volt.: 2,5 KV Sheath gas: N2 set to 45 a. u. Aux. gas: N2 set to 5 a. u. Cap.Temp.: 290 °C HESI Temp.: 260 °C Polarity Pos Mass range: 50-800 u Mass resol.: 25.000 (HCD on, 25 eV) or 100.000 (HCD off), No Lock Mass Forensic Toxicology Use Only U-HPLC / HR-Orbitrap-MS analytical strategy 1. High chromatographic resolution of analytes 2. Accurate mass measurements of MH + ionic species in full scan conditions 3. Study of MH + collision-induced product ions obtained in MS/MS experiments 4. Comparison of experimental and calculated MH + isotopic clusters 5. Examination of the isotopic fine structure (IFS) of the (M+1), (M+2), (M+3) isotopic peaks relative to the monoisotopic (M+0 ) peaks Forensic Toxicology Use Only U-HPLC / HR-Orbitrap-MS analytical strategy 1. High chromatographic resolution of analytes “Classic” amphetamines New A-R drugs RT: 2.36 - 6.07 SM: 3B RT: 2.48 - 6.03 SM: 3B RT: 3.42 NL: 4.01E5 RT: 4.28 NL: 1.09E6 AA: 1367658 m/z= 136.1110-136.1124 F: FTMS AA: 3172486 m/z= 178.1217-178.1235 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] Amphetamine MS ICIS MIX Mephedrone MS ICIS MIX 50 amf-amfsimili-jwh-metilon-propilon 50 amf-amfsimili-jwh-metilon-propilon 0 0 RT: 3.79 NL: 1.62E6 RT: 5.18 NL: 1.55E6 AA: 5728285 m/z= 150.1265-150.1281 F: FTMS AA: 4319203 m/z= 276.1580-276.1608 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] MS ICIS MIX MS ICIS MIX 50 Methamphetamine amf-amfsimili-jwh-metilon-propilon 50 MDPV amf-amfsimili-jwh-metilon-propilon 0 0 RT: 3.70 NL: 2.77E5 RT: 4.73 NL: 2.77E6 AA: 891805 m/z= 180.1005-180.1023 F: FTMS AA: 7724451 m/z= 192.1373-192.1393 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] MS ICIS MIX MS ICIS MIX amf-amfsimili-jwh-metilon-propilon 4-MEC Propylone amf-amfsimili-jwh-metilon-propilon 50 MDA 50 0 0 RT: 3.95 NL: 1.61E6 RT: 3.81 NL: 5.02E5 AA: 5218248 m/z= 194.1161-194.1181 F: FTMS AA: 1744924 m/z= 154.1019-154.1035 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] MS ICIS MIX 4-FA MS ICIS MIX 50 MDMA amf-amfsimili-jwh-metilon-propilon 50 amf-amfsimili-jwh-metilon-propilon 0 0 RT: 4.33 NL: 2.37E6 RT: 4.94 NL: 1.98E5 AA: 7126059 4.60 m/z= 208.1317-208.1337 F: FTMS AA: 559381 m/z= 197.0830-197.0850 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] MS ICIS MIX MS ICIS MIX 50 MDEA amf-amfsimili-jwh-metilon-propilon 50 Cl-Ph-Pip amf-amfsimili-jwh-metilon-propilon 2.47 2.94 3.18 3.85 4.114.76 5.03 5.62 5.79 0 0 RT: 4.60 NL: 2.37E6 RT: 3.30 NL: 1.91E6 4.33 AA: 6351417 m/z= 208.1317-208.1337 F: FTMS AA: 8608603 m/z= 208.0956-208.0976 F: FTMS 100 100 {1,1} + p ESI Full ms [100.00-800.00] {1,1} + p ESI Full ms [100.00-800.00] MBDB MS ICIS MIX MS ICIS MIX 50 amf-amfsimili-jwh-metilon-propilon 50 Methylone amf-amfsimili-jwh-metilon-propilon 2.47 2.94 3.18 3.85 4.114.76 5.03 5.62 5.79 0 0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Time (min) Time (min) Forensic Toxicology Use Only U-HPLC / HR-Orbitrap-MS analytical strategy 2.
Recommended publications
  • Nové Rekreační Drogy

    Nové Rekreační Drogy

    Neurotoxikologie nových „legálních rekreačních drog“ ze skupin empatogenů/entaktogenů a disociativ MUDr. S. Zakharov, CSc. Toxikologické informa ční st ředisko1 Klinika pracovního léka řství Nové rekrea ční drogy („Legal Highs“) - pojem • Nové syntetické psychoaktivní látky neuvedené v Jednotné Úmluv ě o omamných látkách, v zákonu č. 167/1998 Sb.; • Prodávají se legáln ě přes internet („smartshops“, „rostliny- zahrada-online“, „výzkumné chemikálie“, e-inzeráty, aj.) • „Je to jako hra na chemickou ruskou ruletu, protože nejsou údaje o toxicit ě, biometabolitech, fakrmakokinetice…“ (John W. Huffman) • „Clubbers‘ drugs“ – používají ~40% návštěvníků no čních klub ů •Účinky: stimulanty, empatogeny/entaktogeny, halucinogeny (psychedelika, delirianty, disociativa), sedativa, a kombinace… 2 Nové rekrea ční drogy • Výroba v Jihovýchodní Asii, Číně, balení a distribuce v Evropě a Spojených Státech. • Jednoduchá schémata syntézy (2-3 chemické reakce, běžné reagens (toluen, aceton...), vysoká stupe ň chemické čistoty (99%), nízké ceny; • Chemická struktura je podobná struktuře zakázaných (kontrolovaných) psychoaktivních látek; • „Výzkumné chemikálie“ seznam.cz –– 51 odkaz; google.cz – 82 700 odkaz ů; • www.bulkresearchchemicals.com; http://vip- 3 legals.com; www.buyanychem.com MDMA („Extáze“, éčko, koláč) – 3,4- MetylenDioxy-N-Metyl Amfetamin) • Syntezována v r. 1912 (A.Kollisch, Merck), rekrea ční použití od r. 1963, zákaz - 1985 (SZO, USA). • „Droga lásky“: empatogen ( R. Metzner, 1983) nebo entaktogen ( D. Nichols, 1986) - indukce pocit ů empatie, vcítění, soudružnosti, lásky, emoční blízkosti. • MDMA-asistovaná psychoterapie v léčbě posttraumatických stresových poruch (PTSD), (výzkum sponzorován MAPS USA (Multidisciplinary Association For Psychedelic Studies). • V ČR „malé množství“ – do 4 tbl. (400 mg). 4 Mechanismus účinku a toxicita MDMA • Efektivně uvol ňuje a inhibuje zpětné vychytávání SER (afinita k presynaptic- kému SERT), méně – DAT, NAT • Mírně nespecificky inhibuje MAO (A, B) • Mírný agonista 5-HT2-Re (změna percepce), DA2- Re (euforia), NA-Re (symp-mim.
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd

    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
  • Quantification of Drugs of Abuse in Municipal Wastewater Via SPE and Direct Injection Liquid Chromatography Mass Spectrometry

    Quantification of Drugs of Abuse in Municipal Wastewater Via SPE and Direct Injection Liquid Chromatography Mass Spectrometry

    Anal Bioanal Chem (2010) 398:2701–2712 DOI 10.1007/s00216-010-4191-9 ORIGINAL PAPER Quantification of drugs of abuse in municipal wastewater via SPE and direct injection liquid chromatography mass spectrometry Kevin J. Bisceglia & A. Lynn Roberts & Michele M. Schantz & Katrice A. Lippa Received: 2 June 2010 /Revised: 30 August 2010 /Accepted: 2 September 2010 /Published online: 24 September 2010 # US Government 2010 Abstract We present an isotopic-dilution direct injection 50 ng/L. We also present a modified version of this method reversed-phase liquid chromatography–tandem mass spec- that incorporates solid-phase extraction to further enhance trometry method for the simultaneous determination of 23 sensitivity. The method includes a confirmatory LC separa- drugs of abuse, drug metabolites, and human-use markers in tion (selected by evaluating 13 unique chromatographic municipal wastewater. The method places particular emphasis phases) that has been evaluated using National Institute of on cocaine; it includes 11 of its metabolites to facilitate Standards and Technology Standard Reference Material 1511 assessment of routes of administration and to enhance the Multi-Drugs of Abuse in Freeze-Dried Urine. Seven analytes accuracy of estimates of cocaine consumption. Four opioids (ecgonine methyl ester, ecgonine ethyl ester, anhydroecgo- (6-acetylmorphine, morphine, hydrocodone, and oxycodone) nine methyl ester, m-hydroxybenzoylecgonine, p-hydroxy- are also included, along with five phenylamine drugs benzoyl-ecgonine, ecgonine, and anhydroecgonine) were (amphetamine, methamphetamine, 3,4-methylenedioxy- detected for the first time in a wastewater sample. methamphetamine, methylbenzodioxolyl-butanamine, and 3,4-methylenedioxy-N-ethylamphetamine) and two human- Keywords Wastewater . Illicit drugs . Urinary metabolites . use markers (cotinine and creatinine).
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Synthetic Turf Scientific Advisory Panel Meeting Materials

    Synthetic Turf Scientific Advisory Panel Meeting Materials

    California Environmental Protection Agency Office of Environmental Health Hazard Assessment Synthetic Turf Study Synthetic Turf Scientific Advisory Panel Meeting May 31, 2019 MEETING MATERIALS THIS PAGE LEFT BLANK INTENTIONALLY Office of Environmental Health Hazard Assessment California Environmental Protection Agency Agenda Synthetic Turf Scientific Advisory Panel Meeting May 31, 2019, 9:30 a.m. – 4:00 p.m. 1001 I Street, CalEPA Headquarters Building, Sacramento Byron Sher Auditorium The agenda for this meeting is given below. The order of items on the agenda is provided for general reference only. The order in which items are taken up by the Panel is subject to change. 1. Welcome and Opening Remarks 2. Synthetic Turf and Playground Studies Overview 4. Synthetic Turf Field Exposure Model Exposure Equations Exposure Parameters 3. Non-Targeted Chemical Analysis Volatile Organics on Synthetic Turf Fields Non-Polar Organics Constituents in Crumb Rubber Polar Organic Constituents in Crumb Rubber 5. Public Comments: For members of the public attending in-person: Comments will be limited to three minutes per commenter. For members of the public attending via the internet: Comments may be sent via email to [email protected]. Email comments will be read aloud, up to three minutes each, by staff of OEHHA during the public comment period, as time allows. 6. Further Panel Discussion and Closing Remarks 7. Wrap Up and Adjournment Agenda Synthetic Turf Advisory Panel Meeting May 31, 2019 THIS PAGE LEFT BLANK INTENTIONALLY Office of Environmental Health Hazard Assessment California Environmental Protection Agency DRAFT for Discussion at May 2019 SAP Meeting. Table of Contents Synthetic Turf and Playground Studies Overview May 2019 Update .....
  • MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity

    MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: Lmmunocytochemical Evidence for Neurotoxicity

    The Journal of Neuroscience, August 1988, 8(8): 2788-2803 Methylenedioxyamphetamine (MDA) and Methylenedioxymetham- phetamine (MDMA) Cause Selective Ablation of Serotonergic Axon Terminals in Forebrain: lmmunocytochemical Evidence for Neurotoxicity E. O’Hearn,” G. Battaglia, lab E. B. De Souza,’ M. J. Kuhar,’ and M. E. Molliver Departments of Neuroscience, and Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and ‘Neuroscience Branch, Addiction Research Center, National Institute on Drug Abuse, Baltimore, Maryland 21224 The psychotropic amphetamine derivatives 3,4-methylene- The synthetic amphetamine derivatives 3,4-methylenedioxy- dioxyamphetamine (MDA) and 3,4-methylenedioxymetham- amphetamine (MDA) and 3,4-methylenedioxymethamphet- phetamine (MDMA) have been used for recreational and amine (MDMA) are potent mood-altering drugs that have at- therapeutic purposes in man. In rats, these drugs cause large tained public interest (Seymour, 1986) due to their widespread, reductions in brain levels of serotonin (5HT). This study self-administration by young adults (e.g., Klein, 1985). These employs immunocytochemistry to characterize the neuro- drugs have also been proposed for medical use in psychotherapy toxic effects of these compounds upon monoaminergic neu- because they produce augmentation of mood and enhanced in- rons in the rat brain. Two weeks after systemic administra- sight (Naranjo et al., 1967; Yensen et al., 1976; Di Leo, 198 1; tion of MDA or MDMA (20 mg/kg, s.c., twice daily for 4 d), Greer and Tolbert, 1986; Grinspoon and Bakalar, 1986). How- there is profound loss of serotonergic (5HT) axons through- ever, concern has been raised about the safety of these com- out the forebrain; catecholamine axons are completely pounds based on evidence that they may be toxic to brain seroto- spared.
  • Article 22 Regulation for Restriction of Synthetic Drugs

    Article 22 Regulation for Restriction of Synthetic Drugs

    ARTICLE 22 REGULATION FOR RESTRICTION OF SYNTHETIC DRUGS SECTION 22.1 AUTHORITY This regulation is promulgated under the authority granted to the Needham Board of Health under Massachusetts General Laws Chapter 111, Section 31 which states that “boards of health may make reasonable health regulations”. SECTION 22.2 PURPOSE The Needham Board of Health has found that synthetic marijuana, consisting of plant or other material treated with various chemicals or other synthetic substances not approved for human consumption, may be marketed and sold as herbal incense in the greater Boston area, although they are being used in the same manner and for the same purposes as scheduled drugs. In addition, the use of these products has become particularly popular among teens and young adults. Based on information and reports from hospitals, emergency room doctors, and police agencies, individuals who use these products experience dangerous side effects including convulsions, hallucinations, and dangerously elevated heart rates. This is evidence that synthetic marijuana products are harmful if inhaled or consumed, and present a significant public health danger. These synthetic compounds and others have a high potential for abuse and lack of any accepted medical use, these dangerous products, while not approved for human consumption, are marketed and sold in a form that allows for such consumption, putting at risk the individuals who come into contact with them. Therefore, the Needham Board of Health adopts this regulation for the purpose and with the intent to protect the public health and safety of the Town of Needham and its residents from the threat posed by the availability and use of synthetic marijuana, synthetic stimulants, synthetic hallucinogens, and other dangerous products by prohibiting persons from trafficking in, possessing, and using them within the town.
  • Indane Acetic Acid Derivatives and Their Use As Pharmaceutical Agents, Intermediates, and Method of Preparation

    Indane Acetic Acid Derivatives and Their Use As Pharmaceutical Agents, Intermediates, and Method of Preparation

    (19) TZZ___T (11) EP 1 578 715 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07C 57/62 (2006.01) C07C 69/612 (2006.01) 02.03.2011 Bulletin 2011/09 C07C 211/48 (2006.01) C07C 327/48 (2006.01) C07D 261/20 (2006.01) C07D 209/08 (2006.01) (2006.01) (2006.01) (21) Application number: 03800063.4 C07D 307/79 C07D 277/64 C07D 215/06 (2006.01) C07D 333/10 (2006.01) C07D 239/30 (2006.01) C07D 239/26 (2006.01) (22) Date of filing: 19.12.2003 C07D 401/04 (2006.01) A61K 31/33 (2006.01) A61K 31/185 (2006.01) (86) International application number: PCT/US2003/040842 (87) International publication number: WO 2004/058174 (15.07.2004 Gazette 2004/29) (54) INDANE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS, INTERMEDIATES, AND METHOD OF PREPARATION INDANESSIGSÄURE-DERIVATE UND IHRE VERWENDUNG ALS PHARMAZEUTISCHE MITTEL SOWIE ZWISCHENPRODUKTE UND METHODEN ZU IHRER HERSTELLUNG DERIVES D’ACIDE ACETIQUE D’INDANE ET LEUR UTILISATION EN TANT QU’AGENTS PHARMACEUTIQUES ET INTERMEDIAIRES, ET PROCEDE DE PREPARATION CORRESPONDANT (84) Designated Contracting States: • LIANG, Sidney, X. DE ES FR GB IT Bethany, CT 06524 (US) • AKUCHE, Christiana (30) Priority: 20.12.2002 US 435310 P Hamden, CT 06514 (US) • LAVOIE, Rico, C. (43) Date of publication of application: Hamden, CT 06517 (US) 28.09.2005 Bulletin 2005/39 • CHEN, Libing Milford, CT 06460 (US) (73) Proprietor: Bayer Pharmaceuticals Corporation • MAJUMDAR, Dyuti West Haven, CT 06516 (US) Milford, CT 06460 (US) • WICKENS, Philip, L.
  • MDMA, MBDB' and I! I the Classichallucinogens

    MDMA, MBDB' and I! I the Classichallucinogens

    Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi .
  • Recommended Methods for the Identification and Analysis Of

    Recommended Methods for the Identification and Analysis Of

    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
  • General Drug and Explosive Detection

    General Drug and Explosive Detection

    Ζ'HQWDȇV'UXJ'HWHFWLRQDQGΖGHQWLILFDWLRQWHVWNLWVRIIHUEUHDNWKURXJKLQQRYDWLRQVORQJ DZDLWHGE\WKHIRUHQVLFPDUNHW8QWLOUHFHQWO\RQO\GLIILFXOWWRXVHDQGKDUGWRXQGHUVWDQG WHVWNLWVZLWKPDQ\FRQVWUDLQWVDQGOLPLWDWLRQVZHUHDYDLODEOHΖ'HQWDȇVNLWVPDNHWKH WDVNVIDFHGE\SDUHQWVHGXFDWRUVHPSOR\HUVDQGODZHQIRUFHPHQWRIILFHUVHDVLHU IDVWHUIDUVDIHUDQGPRUHFRVWHIIHFWLYHWKDQDQ\VLPLODUNLWDYDLODEOH .H\%HQHILWV .H\0DUNHWV ႑(DV\IDVWDQGVLPSOHWRXVH1RRWKHUWHVWVDUH ႑/DZHQIRUFHPHQW DVVWUDLJKWIRUZDUG ႑0LOLWDU\ ႑$FFXUDWHDQGUHOLDEOHDWH[WUHPHWHPSHUDWXUHV ႑&XVWRPV ႑&OHDUUHVXOWVLQVHFRQGV ႑6HFXULW\DJHQFLHV ႑/RQJVKHOIOLIH XSWR\HDUV ZLWKQRVWRUDJH ႑*RYHUQPHQWDJHQFLHV UHVWULFWLRQV ,'7 '($)%Ζ&Ζ$ ,'7 ,'7 ႑6DIH$FWXDOO\YHU\VDIH1RFRQWDFWZLWK *HQHUDO6FUHHQLQJ ႑3ULVRQV FKHPLFDOVRUVXEVWDQFHV1RLQKDODWLRQRI .HWDPLQH /LTXLG *+% 'UXJV &RUSRUDWH+5GHSDUWPHQWV YDSRUVQRSURWHFWLYHJHDUQHHGHG ႑ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ΖGHQWLILFDWLRQ ႑6DIHWRGLVSRVH6HOIFRQWDLQHGQHXWUDOL]DWLRQ ႑3ULYDWHUHVLGHQFHV )LHOG7HVW.LW ႑6PDOODQGYHU\UXJJHG ႑6FKRROV8QLYHUVLWLHV )LHOG7HVW.LW )LHOG7HVW.LW ႑&DQEHXVHGDQ\ZKHUHDQ\WLPH ႑5HKDELOLWDWLRQIDFLOLWLHV ႑7KHFRORUWHVWLVEDVHGRQWKHVDPHFKHPLVWU\DV ႑ƀ+\GUR[\EXW\ULFDFLG *+% LVDFHQWUDO ႑7KHWHVWGHWHFWVGUXJVLQFOXGLQJFRFDLQH ႑$YDLODEOHZLWKYDULRXVSUREHV ႑%RUGHUFRQWURO IRUWKHVROLGWHVW QHUYRXVV\VWHPGHSUHVVDQWXVHGDVDQ KHURLQDPSKHWDPLQHHFVWDV\DVZHOODVQHZ 7RXFK6ZLSH6QLIIHURU6DPSOHU LQWR[LFDQW GHVLJQHUGUXJV ႑(PHUJHQF\URRPV ႑7KHNLWFRQWDLQVDQRYHOVDPSOHUIRUWKHHDV\ ႑2XUNLWV'2WHVWOLTXLGV WHVWLQJRIOLTXLGV ႑&RPPRQVWUHHWQDPHVLQFOXGH*/LTXLG ႑7KHWHVWLVEDVHGRQDQRYHOFRORUWHVWIRU */LTXLG;/LTXLG(*HRUJLD+RPH%R\ DONDORLGV
  • AGENDA Friday, September 9, 2016 7:00 A.M

    AGENDA Friday, September 9, 2016 7:00 A.M

    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.